Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse Events

Programmed cell death protein-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors are a group of immune checkpoint inhibitors. Since May 2006, there have been 10 immune checkpoint inhibitors targeting PD-1 and PD-L1 for tumor treatment. Although PD-1/PD-L1 inhibitors show promising curative ef...

Description complète

Détails bibliographiques

Auteur principal:	YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng
Format:	Artigo
Langue:	Chinês
Publié:	Chinese General Practice Publishing House Co., Ltd 2022-04-01
Collection:	Zhongguo quanke yixue
Sujets:	|antineoplastic agents, immunological|programmed cell death protein 1|programmed death ligand 1|immunosuppressive agents|monoclonal antibody|adverse event
Accès en ligne:	https://www.chinagp.net/fileup/1007-9572/PDF/yx202101312.pdf
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!